How we source, write, verify, and update every peptide monograph on this site — and what we will not do.
The principle behind the workflow
The verdicts you read on this site are not opinions. They are the output of a structured editorial process designed to do one thing well: turn the available evidence on a peptide into a single, decision-shaped answer that a careful reader can carry with them.
Every step in the process is built around two commitments. First, we follow the evidence — we do not weight by manufacturer prestige, by the loudest forum voice, or by what we’d hope to find. Second, we date everything — every monograph carries a Last reviewed date and a Last verified date, and both of those dates mean something specific. If you cannot tell when a verdict was last checked against current sources, the verdict cannot earn your trust.
This page documents the operational machinery behind that. The companion page How we review peptides covers the verdict taxonomy and the evidence hierarchy; this page covers the editorial process itself — how a monograph gets sourced, written, verified, and updated, and what happens when something on the site turns out to be wrong.
Editorial standards
A peptide monograph that publishes on this site has cleared a fixed set of editorial standards:
It cites real, current sources. Every reference in the monograph’s reference list is verified to exist at the time of publication. We do not include citations we have not located. If a paper is named in the body of a monograph, that paper is real, and the description of its findings is drawn from the paper itself or from the regulatory filing or trial registration that covers it.
It distinguishes evidence from opinion. Mechanism descriptions, trial readouts, regulatory status, and adverse-event language are sourced. Editorial framing — sentences that compare the strength of one body of evidence to another, or that contextualize a verdict — is clearly the editorial voice, not a citation-backed claim.
It is indication-specific. A peptide can be Established for one indication, Promising for a second, and Insufficient evidence for a third. We do not mix verdicts. If a monograph covers more than one indication, the evidence and verdict for each indication are addressed separately.
It surfaces uncertainty rather than hiding it. Insufficient evidence and Cautionary are first-class verdicts on this site. We use them when they are the truthful answer, even when commercial pressure on a peptide topic would push us toward a more confident-sounding verdict.
It carries a date. Every monograph shows two dates near the top of the page: Last reviewed (the most recent editorial pass) and Last verified (the most recent verification of the underlying sources against current information). Those dates are not decorative. They are the receipt for the editorial work behind the page.
It is editable. Every monograph is versioned. When a verdict moves, the previous verdict is preserved in a “Verdict history” section at the bottom of the monograph along with the date of change and the evidence that prompted it. Verdicts do not silently disappear.
How a monograph is sourced and written
The operational workflow, in order:
Topic selection. A peptide enters the queue based on reader interest, regulatory news, or coverage gaps in the existing peptide-information landscape.
Literature pull. A structured search across the published literature — peer-reviewed trials, mechanistic studies, regulatory filings, trial registrations, and recent reviews. The goal at this stage is breadth: identify what exists.
Reference triage. The pulled literature is sorted against the evidence hierarchy. Multi-site randomized trials anchor the verdict; single-arm trials and mechanistic studies fill in context; case reports and forum reports are noted but never anchor a verdict.
Draft. The monograph is written from the triaged reference set, working from the highest-quality evidence down. Sections follow a fixed template: verdict card, mechanism, what the evidence shows, dosing literature, risks and adverse events, regulatory status, where to get it, references. The verdict is assigned at the end of the writing pass, not the beginning — the writing surfaces the verdict; the verdict does not pre-shape the writing.
PR Editorial review. The draft is reviewed by PR Editorial. The reviewer’s job is to challenge the verdict and the supporting prose, not to confirm them. If the review uncovers evidence that was not in the first draft, the verdict is reconsidered before clinical review.
PR Clinical Review. The draft is reviewed by PR Clinical Review for clinical-accuracy issues — dose ranges against current label, contraindications, drug interactions, indication wording precision (label-vs-off-label distinctions), adverse-event language accuracy, mechanism-description correctness, and regulatory-claim specificity. Issues flagged in clinical review are resolved before publication.
Verification. Every cited reference is checked for existence and accuracy of description. Regulatory status claims are checked against the current regulator’s record. Specific numeric claims — effect sizes, hazard ratios, response rates — are checked against the cited paper or filing. The verification pass is the editorial step that locks the Last verified date for the published monograph.
Publication. With a verdict, a Last reviewed date, a Last verified date, a Next review by date, and a versioned reference list.
We do not preview a monograph for the peptide’s manufacturer, distributor, or affiliate partner before publication. They see the published version when readers do.
Source verification
The verification step is the most important editorial control on this site. It is the difference between a monograph that sounds researched and one that has been researched, and it is the discipline behind the Last verified date that every monograph displays.
A verification pass on a single monograph checks the following, at minimum:
Cited references exist. Every paper named in the monograph is located in the relevant index (PubMed, EMA EPAR, FDA Drugs@FDA, ClinicalTrials.gov, or the equivalent primary source). Citations that cannot be located are removed or replaced before publication.
Cited findings match the source. Effect sizes, primary endpoints, and adverse-event language are verified against the cited paper or filing rather than against secondary summaries.
Regulatory status is current. Approval status, indication wording, and label changes are checked against the regulator’s current record. We update the regulatory table to reflect any indication added, withdrawn, or expanded since the last verification.
Sponsor and commercial detail is current. Pharma reorganizations, brand-name changes, generic availability, and discontinuations are checked. A drug whose original sponsor has been acquired, whose brand has been rebranded, or whose commercial form has been withdrawn carries that fact on the page.
Post-publication regulatory news is captured. Trial readouts, label expansions, new approvals, and safety actions that have published since the previous verification pass are reviewed. Where they materially change the verdict or the supporting evidence, the monograph is updated and re-published with a fresh Last verified date.
The verification process is documented internally on a per-monograph basis — what was checked, what changed, and what required a verdict revision — so that the editorial trail behind any specific page can be reconstructed.
What “Last verified” means
Every monograph carries a small line of text below the verdict card that reads, for example, Last verified: April 27, 2026. The link points back to this page.
That date means: as of that day, an editorial-team member has run the verification pass described above against the monograph and either confirmed it remains current or updated it to reflect what has changed. The date is not a publication date. It is a freshness signal — a real one, backed by a real check.
A monograph whose Last verified date is older than its assigned re-verification cadence (see below) is flagged internally as overdue, and the editorial team prioritizes it for the next verification cycle. The flag is operational; it shapes the work queue, not the public-facing page. What you see on the page is always the most recent verified state.
How often a monograph is re-verified
Not every peptide needs the same re-verification cadence. A drug with active Phase 3 readouts and frequent regulatory action shifts the underlying evidence faster than a drug whose label has been stable for a decade or a research-only peptide whose evidence base has not meaningfully changed in years. We assign each monograph to one of three cadence tiers and re-verify accordingly:
High velocity — every 60 days. Drugs with active pipeline activity, recent regulatory action, or expected near-term news. Most of the GLP-1 / incretin-class drugs sit here. Recently-approved rare-disease therapies sit here for the period during which their label is likely to expand.
Medium velocity — every 180 days. Established or research-active drugs with slower regulatory cadence. Most of the long-approved peptide therapeutics sit here.
Low velocity — every 365 days. Drugs whose evidence base is unlikely to change inside a year — gray-market peptides without an active development pipeline, decades-old peptide drugs with stable labels, and research-stage peptides where publication cadence is slow. These monographs are still re-verified on schedule; the schedule simply reflects that the underlying field is not moving fast.
A monograph can be re-verified earlier than its assigned cadence if a major event lands — a new approval, a withdrawal, a high-impact trial readout, or a credible safety signal. Velocity tier is a floor, not a ceiling. Specific events override the schedule.
When something on the site changes
Verdicts move. Effect sizes get refined. Approvals expand. Drugs get withdrawn. The evidence base behind any peptide is alive, and our job is to keep the page in step with it.
When a re-verification pass surfaces material change, three things happen:
The monograph is updated. The body, the regulatory table, and the reference list are revised to reflect current information. The verdict card may move — Investigational may become Promising, Established may add or lose an indication.
The change is recorded. A Verdict history section at the bottom of the monograph records the previous verdict, the date the new verdict took effect, and a one- or two-sentence note on the evidence that prompted the change. The previous verdict is preserved, not erased.
The dates are refreshed. A new Last verified date is set. The Next review by date is recomputed from the velocity-tier schedule. The page becomes the new current-state record.
Readers who encounter a monograph that disagrees with a previous version they remember are encouraged to read the Verdict history section. The history is part of the page, not buried in a separate log.
Corrections and reader feedback
If you spot something on this site that you believe is wrong — a misstated effect size, a missed approval, an outdated price, a verdict you think the evidence does not support — write to [email protected] with the source you think we missed. We read every one.
We do not change verdicts because someone is angry. We have changed verdicts because someone showed us a paper we had not weighted properly. The corrections inbox is monitored on a continuous cadence; specific factual corrections we accept are reflected in the next published verification of the affected monograph, with the change recorded in the Verdict history section and credited to “external reader correction” without naming the reader unless the reader requests credit.
If you represent a peptide brand and want to submit evidence for editorial consideration, write to [email protected] with links to published, peer-reviewed studies. Brand-prepared white papers, internal data, and unpublished results do not move verdicts on this site.
Conflicts of interest and commercial relationships
Peptide Repo earns revenue through affiliate relationships with selected fulfillment partners. We do not accept advertising. We do not accept payment for verdicts, for placement, or for review timing. The full disclosure of how we make money is on the About page; every monograph that is monetized through an affiliate relationship carries an explicit affiliate disclosure on the page itself.
Where a monograph’s verdict or evidence framing has any plausible commercial implication, the editorial team treats the verdict assignment with extra scrutiny — not less. A peptide that is structurally important to our affiliate revenue is not given the benefit of the doubt; it is given the closer reading.
What this method cannot do
We are not blind to what an editorial-synthesis methodology cannot capture, and we will not pretend otherwise.
We do not run trials. We do not generate primary research. We do not have lab access. The evidence base we summarize is the evidence base that exists in the literature; if a peptide has not yet been studied, the most truthful thing we can say is that it has not yet been studied.
We do not provide medical advice. A verdict tells you the state of a field. It does not tell you what is right for you, what interacts with the medications you are already taking, or what dose any individual person should use. That is the work of a clinician relationship, which sits one layer above us.
We will sometimes be wrong. The literature changes. New trials publish. Regulatory action lands. Verdicts move. The Verdict history on every monograph and the [email protected] inbox are the receipts for that.
Version and currency of this page
This page is part of the editorial standards documented on this site. When the methodology behind a monograph changes — when we add a verification check, change a velocity tier definition, revise the corrections process, or modify the editorial review chain — this page is updated to match, and the date below records the change.
Last revised: 2026-04-27 — first published version